@techreport{oai:kindai.repo.nii.ac.jp:00019739,
 author = {工藤, 正俊 and 西田, 直生志},
 month = {},
 note = {研究成果の概要（和文）：血清分泌型microRNA(miR)定量によるソラフェニブ効果予測を試みた。screening、validation cohortにより、対象miR絞り込んだ。3ヶ月以上のdisease control (DC)例とnon-DC例、健常者間で血清中miR-181a-5を定量したところ、non-DC群ではDC群、健常者群と比較して有意にmiR-181a-5量は低値であった。BCLC-stage C例を対象として、多変量解析を行い、血清miR-181a-5量が独立して治療開始後のDC、全生存期間に影響することを確認した。血清中miR-181a-5定量により、病勢制御効果が予測できる可能性がある。
研究成果の概要（英文）：The aim of this study was to clarify the specific miRNAs in serum that could predict the early response of HCC to sorafenib treatment.Analyzing the sera from screening cohort,we selected five miRNAs. Through further analysis using a validation cohort and healthy control subjects, we found that miR-181a-5p and miR-339-5p showed significant differences in serum levels among patients with partial response (PR), stable disease (SD), and progressive disease (PD). We also analyzed the factors associated with disease control (DC); patients with DC showed a significantly higher level of serum miR-181a-5p than non-DC patients or healthy control subjects. We further conducted multivariate analysis among HCC patients with Barcelona Clinic Liver Cancer stage C using extrahepatic metastasis, serum decarboxiprothrombin and miR-181a-5p levels as covariables; serum miR-181a-5p was the only independent factor for achieving DC and affecting overall survival., 研究種目：基盤研究(C);  研究期間：2015～2017;   課題番号：15K09028;   研究分野：消化器内科;   科研費の分科・細目：, application/pdf},
 title = {血清分泌型マイクロRNAを用いたソラフェニブ治療効果予測マーカーの開発},
 year = {2018},
 yomi = {クドウ, マサトシ and ニシダ, ナオシ}
}